Cipla Q1 results preview: Analysts attribute the likely dull performance due to the high base of last year, and the reduction in revenue contribution from Covid-19 therapies in the recent quarter.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
